Paul Stockdale
Fortuna: 15 964 $ al 31/05/2026
Fortuna: 15 964 $ al 31/05/2026
Paul Stockdale currently works at Oxford BioDynamics Plc, as Chief Financial Officer & Executive Director.
Mr. Stockdale also formerly worked at e-Therapeutics Plc, as Financial Controller from 2012 to 2017 and Deloitte & Touche LLP UK, as Senior Manager from 1996 to 2004.
Mr. Stockdale received his graduate degree from the University of Cambridge.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
OXFORD BIODYNAMICS PLC 0,15 % | 10/11/2025 | 6.411.252 ( 0,15 % ) | 15 964 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| OXFORD BIODYNAMICS PLC | Director Financiero/CFO | 15/09/2017 |
| Empresas | Cargo | Fin |
|---|---|---|
| E-THERAPEUTICS PLC | Comptroller/Controller/Auditor | 01/09/2017 |
Deloitte & Touche LLP UK
Deloitte & Touche LLP UK Miscellaneous Commercial ServicesCommercial Services Provides financial advisory and accounting services | Corporate Officer/Principal | 01/01/2004 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
e-Therapeutics Plc
e-Therapeutics Plc BiotechnologyHealth Technology Discovers and develops drugs | Health Technology |
University of Cambridge
University of Cambridge Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Deloitte & Touche LLP UK
Deloitte & Touche LLP UK Miscellaneous Commercial ServicesCommercial Services Provides financial advisory and accounting services | Commercial Services |
Oxford BioDynamics Plc
Oxford BioDynamics Plc BiotechnologyHealth Technology Discovers and develops novel biomarkers | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.